NIRAJ CHAPLA: Open Payments
NPI 1659508067 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$668 in 22 payments from 8 companies in 2025. Trend: 2023 $15 · 2024 $439 · 2025 $668
Food & beverage: $668
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $177 |
| Janssen Pharmaceuticals, Inc | 3 | $151 |
| E.R. Squibb & Sons, L.L.C. | 2 | $86 |
| ABBVIE INC. | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 4 | $64 |
| Lundbeck LLC | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Neurocrine BioSciences, Inc. | 2 | $32 |
Products named: CAPLYTA, INVEGA SUSTENNA, COBENFY, VRAYLAR, FANAPT, REXULTI, Auvelity, INGREZZA.
Industry payments across MD — which companies pay providers there.
